# Anang A Shelat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5394682/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 101 papers | 5,249 citations | 94433 37 h-index | 98798 67 g-index |
| 110 all docs | 110 docs citations | 110 times ranked | 9707 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | An Evolutionarily Conserved Residue in ABCG2 Regulates the Transport Cycle and Inhibitor Activity. FASEB Journal, 2022, 36, . | 0.5 | 0 |
| 2 | INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.. Neuro-Oncology, 2022, 24, i188-i188. | 1.2 | 0 |
| 3 | MAIP: a web service for predicting bloodâ€stage malaria inhibitors. Journal of Cheminformatics, 2021, 13, 13. | 6.1 | 20 |
| 4 | Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood, 2021, 137, 1628-1640. | 1.4 | 25 |
| 5 | Evaluating and evolving a screening library in academia: the St Jude approach. Drug Discovery Today, 2021, 26, 1060-1069. | 6.4 | 6 |
| 6 | Modelâ€based evaluation of imageâ€guided fractionated wholeâ€brain radiation therapy in pediatric diffuse intrinsic pontine glioma xenografts. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 599-610. | 2.5 | 3 |
| 7 | Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nature Communications, 2021, 12, 4089. | 12.8 | 27 |
| 8 | SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents. Molecular Cancer Therapeutics, 2021, 20, 2151-2165. | 4.1 | 6 |
| 9 | Using response surface models to analyze drug combinations. Drug Discovery Today, 2021, 26, 2014-2024. | 6.4 | 4 |
| 10 | Small Molecule Sequestration of the Intrinsically Disordered Protein, p27Kip1, Within Soluble Oligomers. Journal of Molecular Biology, 2021, 433, 167120. | 4.2 | 16 |
| 11 | Data vignettes for the application of response surface models in drug combination analysis. Data in Brief, 2021, 38, 107400. | 1.0 | 0 |
| 12 | 17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma. IScience, 2021, 24, 101996. | 4.1 | 7 |
| 13 | Phenylâ€Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angewandte Chemie - International Edition, 2021, 60, 26663-26670. | 13.8 | 45 |
| 14 | Loss of PTEN in Pediatric AML Confers Sensitivity to PARP Inhibition. Blood, 2021, 138, 3446-3446. | 1.4 | 0 |
| 15 | A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. European Journal of Cancer, 2020, 137, 204-213. | 2.8 | 39 |
| 16 | Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. Cancer Research, 2020, 80, 3507-3518. | 0.9 | 28 |
| 17 | MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nature Communications, 2020, 11, 913. | 12.8 | 66 |
| 18 | A critical evaluation of methods to interpret drug combinations. Scientific Reports, 2020, 10, 5144. | 3.3 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | ABCG2 requires a single aromatic amino acid to â€œclampâ€•substrates and inhibitors into the binding pocket. FASEB Journal, 2020, 34, 4890-4903. | 0.5 | 30 |
| 20 | A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 2019, 10, 2189. | 12.8 | 26 |
| 21 | Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents. European Journal of Medicinal Chemistry, 2019, 164, 391-398. | 5.5 | 7 |
| 22 | Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Letters, 2019, 442, 262-270. | 7.2 | 23 |
| 23 | Determining the Molecular Characteristics of How Ligands Interact with an ABC Transporter. FASEB Journal, 2019, 33, 507.4. | 0.5 | 0 |
| 24 | Novel vitexin-inspired scaffold against leukemia. European Journal of Medicinal Chemistry, 2018, 146, 501-510. | 5.5 | 17 |
| 25 | Establishing a Preclinical Multidisciplinary Board for Brain Tumors. Clinical Cancer Research, 2018, 24, 1654-1666. | 7.0 | 12 |
| 26 | The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. Journal of Molecular Graphics and Modelling, 2018, 81, 197-210. | 2.4 | 18 |
| 27 | Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 25-36. | 3.0 | 23 |
| 28 | Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria. F1000Research, 2018, 6, 1136. | 1.6 | 6 |
| 29 | Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell, 2018, 34, 411-426.e19. | 16.8 | 106 |
| 30 | Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. SLAS Discovery, 2018, 23, 164-173. | 2.7 | 14 |
| 31 | Is Inhibitor Binding the Sole Requirement in Determining Inhibition of ABCG2 Mediated Transport?. FASEB Journal, 2018, 32, 693.9. | 0.5 | 0 |
| 32 | Multiplex CRISPR/Cas9-Based Genome Editing of Mouse Hematopoietic Stem Cells Recapitulates Acute Erythroid Leukemia and Identifies Therapeutic Targets. Blood, 2018, 132, 5-5. | 1.4 | 0 |
| 33 | Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition. Journal of Chemical Information and Modeling, 2017, 57, 445-453. | 5.4 | 15 |
| 34 | Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention. Cell Reports, 2017, 19, 1640-1653. | 6.4 | 127 |
| 35 | Orthotopic patient-derived xenografts of paediatric solid tumours. Nature, 2017, 549, 96-100. | 27.8 | 223 |
| 36 | Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway. ACS Chemical Biology, 2017, 12, 2436-2447. | 3.4 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Research, 2017, 77, 4626-4638. | 0.9 | 42 |
| 38 | Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening. PLoS Neglected Tropical Diseases, 2017, 11, e0006157. | 3.0 | 23 |
| 39 | Blocking an N-terminal acetylationâ€“dependent protein interaction inhibits an E3 ligase. Nature Chemical Biology, 2017, 13, 850-857. | 8.0 | 80 |
| 40 | Targeting the cell cycle for cancer therapy in rhabdomyosarcoma.. Journal of Clinical Oncology, 2017, 35, 10535-10535. | 1.6 | 1 |
| 41 | PARP inhibitor combination therapy in desmoplastic small round cell tumors.. Journal of Clinical Oncology, 2017, 35, e23212-e23212. | 1.6 | 4 |
| 42 | Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria. F1000Research, 2017, 6, 1136. | 1.6 | 7 |
| 43 | A biomarker-guided approach to combining PARP inhibitors with radiotherapy in pediatric solid tumors.. Journal of Clinical Oncology, 2017, 35, 10556-10556. | 1.6 | 1 |
| 44 | The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624. | 1.8 | 55 |
| 45 | BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action. Scientific Reports, 2016, 6, 25523. | 3.3 | 63 |
| 46 | Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 77, 1231-1243. | 2.3 | 41 |
| 47 | Diversity-oriented natural product platform identifies plant constituents targeting Plasmodium falciparum. Malaria Journal, 2016, 15, 270. | 2.3 | 4 |
| 48 | Synthesis and evaluation of colletoic acid core derivatives. European Journal of Medicinal Chemistry, 2016, 110, 126-132. | 5.5 | 8 |
| 49 | Preclinical studies of 5-fluoro-2â€²-deoxycytidine and tetrahydrouridine in pediatric brain tumors. Journal of Neuro-Oncology, 2016, 126, 225-234. | 2.9 | 11 |
| 50 | The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Developmental Biology, 2016, 411, 287-293. | 2.0 | 63 |
| 51 | Nuclear ULK1 promotes cell death in response to oxidative stress through PARP1. Cell Death and Differentiation, 2016, 23, 216-230. | 11.2 | 61 |
| 52 | Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis. PLoS ONE, 2016, 11, e0149439. | 2.5 | 17 |
| 53 | Discovery of Small Molecules that Inhibit the Disordered Protein, p27Kip1. Scientific Reports, 2015, 5, 15686. | 3.3 | 70 |
| 54 | A High-Throughput Screen Reveals New Small-Molecule Activators and Inhibitors of Pantothenate Kinases. Journal of Medicinal Chemistry, 2015, 58, 1563-1568. | 6.4 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Development and characterization of a human orthotopic neuroblastoma xenograft. Developmental Biology, 2015, 407, 344-355. | 2.0 | 30 |
| 56 | Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clinical Cancer Research, 2015, 21, 3216-3229. | 7.0 | 58 |
| 57 | ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. Cancer Research, 2015, 75, 3879-3889. | 0.9 | 30 |
| 58 | Targeting the DNA Repair Pathway in Ewing Sarcoma. Cell Reports, 2014, 9, 829-840. | 6.4 | 141 |
| 59 | (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5455-62. | 7.1 | 199 |
| 60 | A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia. Journal of Biomolecular Screening, 2014, 19, 158-167. | 2.6 | 10 |
| 61 | Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. Cancer Cell, 2014, 25, 516-529. | 16.8 | 128 |
| 62 | Development of a Cell-Based, High-Throughput Screening Assay for ATM Kinase Inhibitors. Journal of Biomolecular Screening, 2014, 19, 538-546. | 2.6 | 32 |
| 63 | UPLC-MS-ELSD-PDA as a Powerful Dereplication Tool to Facilitate Compound Identification from Small-Molecule Natural Product Libraries. Journal of Natural Products, 2014, 77, 902-909. | 3.0 | 41 |
| 64 | Ligand Binding Mode Prediction by Docking: Mdm2/Mdmx Inhibitors as a Case Study. Journal of Chemical Information and Modeling, 2014, 54, 648-659. | 5.4 | 35 |
| 65 | Targeted Inhibition of the MLL Transcriptional Complex By Proteosome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia. Blood, 2014, 124, 972-972. | 1.4 | 8 |
| 66 | Incorporating PARP inhibitors in translational studies for Ewingâ€™s sarcoma.. Journal of Clinical Oncology, 2014, 32, e21025-e21025. | 1.6 | 0 |
| 67 | Preclinical evaluation of PARP inhibitors in combination with DNA-damaging agents in a Ewing sarcoma orthotopic xenograft model.. Journal of Clinical Oncology, 2014, 32, 10073-10073. | 1.6 | 0 |
| 68 | Molecular analysis of solid tumors (MAST): A protocol for comprehensive preclinical evaluation of pediatric solid tumors.. Journal of Clinical Oncology, 2014, 32, 10036-10036. | 1.6 | 0 |
| 69 | Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 325-339. | 9.7 | 35 |
| 70 | Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 468. | 9.7 | 1 |
| 71 | Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. Cancer Cell, 2013, 24, 710-724. | 16.8 | 252 |
| 72 | Identification of Small Molecule Activators of BMP Signaling. PLoS ONE, 2013, 8, e59045. | 2.5 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Global Phenotypic Screening for Antimalarials. Chemistry and Biology, 2012, 19, 116-129. | 6.0 | 120 |
| 74 | An Integrated InÂVitro and InÂVivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. Cancer Cell, 2011, 20, 384-399. | 16.8 | 105 |
| 75 | A High-Content Screen Identifies Inhibitors of Nuclear Export of Forkhead Transcription Factors. Journal of Biomolecular Screening, 2011, 16, 394-404. | 2.6 | 12 |
| 76 | An Automated Approach to Efficiently Reformat a Large Collection of Compounds. Current Chemical Genomics, 2011, 5, 42-47. | 2.0 | 5 |
| 77 | Chemical genetics of Plasmodium falciparum. Nature, 2010, 465, 311-315. | 27.8 | 515 |
| 78 | Discovery of Potent and Selective Inhibitors of Trypanosoma brucei Ornithine Decarboxylase. Journal of Biological Chemistry, 2010, 285, 16771-16781. | 3.4 | 33 |
| 79 | Optimization of a Non-Radioactive High-Throughput Assay for Decarboxylase Enzymes. Assay and Drug Development Technologies, 2010, 8, 175-185. | 1.2 | 15 |
| 80 | Identification and Characterization of the First Small Molecule Inhibitor of MDMX. Journal of Biological Chemistry, 2010, 285, 10786-10796. | 3.4 | 171 |
| 81 | Automated High-Throughput System to Fractionate Plant Natural Products for Drug Discovery. Journal of Natural Products, 2010, 73, 751-754. | 3.0 | 79 |
| 82 | A road less traveled by: Exploring a decade of Ellman chemistry. Bioorganic and Medicinal Chemistry, 2009, 17, 1088-1093. | 3.0 | 4 |
| 83 | Structure-Guided Development of Selective TbcatB Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 6489-6493. | 6.4 | 25 |
| 84 | Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2883-2885. | 2.2 | 52 |
| 85 | Development of Potent Purine-Derived Nitrile Inhibitors of the Trypanosomal Protease TbcatB. Journal of Medicinal Chemistry, 2008, 51, 545-552. | 6.4 | 58 |
| 86 | Assay Optimization and Screening of RNA-Protein Interactions by AlphaScreen. Journal of Biomolecular Screening, 2007, 12, 946-955. | 2.6 | 38 |
| 87 | Design of a selective chemical probe for class I PDZ domains. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 546-548. | 2.2 | 13 |
| 88 | The interdependence between screening methods and screening libraries. Current Opinion in Chemical Biology, 2007, 11, 244-251. | 6.1 | 54 |
| 89 | Scaffold composition and biological relevance of screening libraries. Nature Chemical Biology, 2007, 3, 442-446. | 8.0 | 164 |
| 90 | Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei. Chemical Biology and Drug Design, 2006, 67, 355-363. | 3.2 | 97 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Searching for New Antimalarial Therapeutics amongst Known Drugs. Chemical Biology and Drug Design, 2006, 67, 409-416. | 3.2 | 110 |
| 92 | A High-Throughput Screening Method to Identify Small Molecule Inhibitors of Thyroid Hormone Receptor Coactivator Binding. Science Signaling, 2006, 2006, pl3-pl3. | 3.6 | 27 |
| 93 | High-throughput assays for promiscuous inhibitors. , 2005, 1, 146-148. | | 300 |
| 94 | Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators. Journal of Biological Chemistry, 2005, 280, 43048-43055. | 3.4 | 96 |
| 95 | A Solid-Phase Approach to the Phallotoxins:Â Total Synthesis of [Ala7]-Phalloidin. Journal of Organic Chemistry, 2005, 70, 4578-4584. | 3.2 | 38 |
| 96 | Catalysis, Specificity, and ACP Docking Site of Streptomyces coelicolor Malonyl-CoA:ACP Transacylase. Structure, 2003, 11, 147-154. | 3.3 | 125 |
| 97 | Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorganic and Medicinal Chemistry, 2003, 11, 4113-4120. | 3.0 | 62 |
| 98 | Structurally Conserved Amino Acid W501 Is Required for RNA Helicase Activity but Is Not Essential for DNA Helicase Activity of Hepatitis C Virus NS3 Protein. Journal of Virology, 2003, 77, 571-582. | 3.4 | 23 |
| 99 | Nanomolar Affinity Small Molecule Correctors of Defective Î”F508-CFTR Chloride Channel Gating. Journal of Biological Chemistry, 2003, 278, 35079-35085. | 3.4 | 192 |
| 100 | Phenylâ€Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angewandte Chemie, 0, , . | 2.0 | 1 |
| 101 | Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , . | 0.4 | 0 |